XYLOBIOSE [6860-47-5]
Cat# T5788-10mg
Size : 10mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
XYLOBIOSE
Copy Product Info
XYLOBIOSE ia a natural product,and exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.
Cas No. 6860-47-5
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.93%
Appearance:Solid
Color:White
COA LCMS HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | XYLOBIOSE ia a natural product,and exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders. |
| In vivo | Mice received a 60% high-fat diet supplemented with 15% d-xylose, 10% XYLOBIOSE, or 15% XYLOBIOSE as part of the total sucrose content of the diet for ten weeks.?Body weight, fat and liver weights, fasting blood glucose, and blood lipids levels were significantly reduced with XYLOBIOSE supplementation.?Levels of leptin and adipokine were also improved and lipogenic and adipogenic genes in mesenteric fat and liver were down-regulated with XYLOBIOSE supplementation.?Furthermore, pro-inflammatory cytokines, fatty acid uptake, lipolysis, and β-oxidation-related gene expression levels in mesenteric fat were down-regulated with XYLOBIOSE supplementation[1].XYLOBIOSE exhibits anti-diabetic, hypolipogenic, and anti-inflammatory effects via regulation of the miR-122a/33a axis in db/db mice[2]. |
| Animal Research | The mice were randomized into five groups: (a) a control group (Ctrl, n = 10) which received a diet of modified American Institute of Nutrition (AIN)-93G (17% of the calories are from fat); (b) a high fat diet (HFD)-induced obesity control group (HF, n = 13) which received a HFD comprised of 60% fat; (c) a xylose 15% group (Xylo 15) which received a HFD with 15% of the total sucrose replaced with d-xylose (n = 13); (d) an XYLOBIOSE 10% group (XYLOBIOSE 10, n = 13) which received a HFD with 10% of the total sucrose replaced by XYLOBIOSE; and (e) an XYLOBIOSE 15% group (XYLOBIOSE 15, n = 12) which received a HFD with 15% of the total sucrose replaced by XYLOBIOSE. Commercially available D-xylose was included as a positive control and was administered at a dose comparable to XYLOBIOSE. The mice were maintained on these diets according to their group for ten weeks prior to sacrifice. Body weight and food intake were measured twice a week. |
| Molecular Weight | 282.24 |
| Formula | C10H18O9 |
| Cas No. | 6860-47-5 |
| Smiles | O[C@@H]1CO[C@@H](O[C@@H]2COC(O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O |
| Relative Density. | 1.61 g/cm3 (Predicted) |
| Storage | Keep away from direct sunlight,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (885.77 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 10 mg/mL (35.43 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||